Novo Nordisk Faces Investor Skepticism Despite CEO’s Turnaround Efforts

Despite Chief Executive Mike Doustdar’s claims that the market is underestimating the long-term potential of the company’s pharmaceutical pipeline, investors remain cautious about future growth prospects.

1 Sept, 14:06 — 1 Sept, 14:06

Post Share

Sources

Showing 1 of 1 sources

NYTMostly Factual1d ago

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.

By Eshe Nelson

Read full article →

Novo Nordisk Faces Investor Skepticism Despite CEO’s Turnaround Efforts

Sources

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Related Stories

Chevron Announces $7 Billion Plan to Double Oil Production in Venezuela

Daktronics Shares Surge on Strong First-Quarter Earnings Beat

Major Corporations Announce Quarterly Dividend Payouts

Elliott Management Takes Stake in Deutsche Telekom to Block T-Mobile Merger